Logo Image
News
FDA UpdatesLaw and AdvocacyTechnology TrendsViewpointsAll News
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Resources
Disease Awareness White Board VideoAmerican Pharmacists MonthSponsored ResourcesCME/CEPartners
More
Publications
Drug Topics JournalTotal Pharmacy JournalSubmission of ArticlesSupplements And Featured Publications
Events
Virtual EventsTotal Pharmacy Solutions Summit
Business
Business StrategiesPatient ServicesPharmacy InventoryLaw and RegulationsTechnology and DataAll Business News
Practice Type
Independent PharmacyChain PharmacySpecialty PharmacyHealth System PharmacyPharmacy Technicians
Total Pharmacy

Subscribe

  • News
  • Watch
  • Conferences
  • Resources
  • Publications
  • Events
  • Business
  • Practice Type
  • Subscribe
  • Total Pharmacy
  • Allergy
  • Asthma
  • Autoimmune Diseases
  • Biosimilars
  • COVID-19
  • Cannabidiol (CBD)
  • Cardiology
  • Compounding
  • Continuous Glucose Monitoring
  • Dermatology
  • Diabetes
  • Digestive Health
  • Endocrinology
  • Eye Health
  • Generics
  • HIV
  • Headache and Migraine
  • Immunization
  • Infectious Disease
  • Influenza
  • Insulin Management
  • Medical Devices
  • Mental and Behavioral Health
  • Neurology
  • OTC
  • Obesity Management
  • Oncology
  • Pain Management
    • Nonopioid Pain Management
  • Pediatrics
  • Pneumococcal
  • Public Health
  • Rare Diseases
  • Respiratory
  • Rheumatology
  • Shingles
  • Specialty Pharmacy
  • Substance Use Disorder
  • Technology and Data
  • Veterinary Pharmacy
  • Women's Health
  • Wound Care Awareness
Spotlight -
American Pharmacists Month|
Over the Counter|
FDA Updates|
Total Pharmacy
Advertisement

Katelyn Yamartino, PharmD

Advertisement

Articles by Katelyn Yamartino, PharmD

heart disease

Vericiguat (Verquvo) for Heart Failure With Reduced Ejection Fraction

ByKatelyn Yamartino, PharmD,Kevin W. Chamberlin, PharmD
March 16th 2021

A new drug review for vericiguat, indicated for heart failure, reports efficacy and safety data.

Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults

ByKatelyn Yamartino, PharmD,Kevin W. Chamberlin, PharmD
November 11th 2020

An overview of the use of satralizumab-mwge (Enspryng; Genentech) in neuromyelitis optica spectrum disorder (NMOSD).

Advertisement

Latest Updated Articles

  • Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults
    Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults

    November 11th 2020



Advertisement
Advertisement

Trending on Drug Topics

1

DOL Finalizes PBM Transparency Rule with Implications for Employers, Independent Pharmacies

2

How Automated Vouchers Reduce Costs Without Hurting Pharmacy Margins

3

What Pharmacists Should Know About Shifting Peptide Policy

4

What Wyden’s 2027 PBM Agenda Could Mean for Independent Pharmacies

5

Severe Anemia Linked With Increase in Maternal Heart Failure Risk

  • About
  • Advertise
  • Editorial
  • Editorial Board
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • AdvanCE
  • Total Pharmacy
Drug Topics
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us